Related references
Note: Only part of the references are listed.The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1
Junko H. Ohyashiki et al.
CANCER SCIENCE (2009)
Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab
Winnie Yeo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Patient-reported outcomes of deferasirox (Exjade (R), ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis
Elliott Vichinsky et al.
ACTA HAEMATOLOGICA (2008)
Clinical application of deferasirox: Practical patient management
Elliott Vichinsky
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Switch from Type II to I Fas/CD95 Death Signaling on In Vitro Culturing of Primary Hepatocytes
Dorothee Walter et al.
HEPATOLOGY (2008)
Fulminant hepatitis and late onset hepatic failure in Japan
Kenji Fujiwara et al.
HEPATOLOGY RESEARCH (2008)
Etiology and prognosis of fulminant hepatitis in adults
Philippe Ichai et al.
LIVER TRANSPLANTATION (2008)
Fulminant hepatic failure: etiology and indications for liver transplantation
Daniel Gotthardt et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Protection of human and murine hepatocytes against Fas-induced death by transferrin and iron
VA Lesnikov et al.
APOPTOSIS (2006)
Liver iron deposits in hepatitis B patients: Association with severity of liver disease but not with hemochromatosis gene mutations
AL Martinelli et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2004)
Fas-mediated apoptosome formation is dependent on reactive oxygen species derived from mitochondrial permeability transition in Jurkat cells
T Sato et al.
JOURNAL OF IMMUNOLOGY (2004)
Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus
M Rivero et al.
JOURNAL OF VIRAL HEPATITIS (2002)
Share Paper
